Tocqueville Asset Management L.P. reduced its stake in shares of Bristol-Myers Squibb Co. (NYSE:BMY) by 0.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 742,609 shares of the biopharmaceutical company’s stock after selling 4,969 shares during the period. Tocqueville Asset Management L.P.’s holdings in Bristol-Myers Squibb were worth $40,041,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in BMY. WESPAC Advisors SoCal LLC raised its stake in Bristol-Myers Squibb by 5.1% in the second quarter. WESPAC Advisors SoCal LLC now owns 1,538 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 75 shares during the last quarter. First New York Securities LLC NY acquired a new stake in Bristol-Myers Squibb during the third quarter valued at approximately $108,000. State of Alaska Department of Revenue acquired a new stake in Bristol-Myers Squibb during the third quarter valued at approximately $109,000. Jolley Asset Management LLC raised its stake in Bristol-Myers Squibb by 4.0% in the second quarter. Jolley Asset Management LLC now owns 2,092 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 80 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Bristol-Myers Squibb during the second quarter valued at approximately $163,000. 68.84% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb Co. (NYSE:BMY) traded down 0.18% during trading on Wednesday, hitting $56.26. 1,189,800 shares of the company were exchanged. Bristol-Myers Squibb Co. has a 12 month low of $49.03 and a 12 month high of $77.12. The company has a market capitalization of $94.02 billion, a price-to-earnings ratio of 28.14 and a beta of 0.90. The company has a 50-day moving average of $52.72 and a 200-day moving average of $62.87.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.12. Bristol-Myers Squibb had a net margin of 18.54% and a return on equity of 28.98%. The company had revenue of $4.83 billion for the quarter, compared to the consensus estimate of $4.76 billion. During the same quarter in the prior year, the firm earned $0.39 earnings per share. The company’s revenue for the quarter was up 21.0% compared to the same quarter last year. Analysts forecast that Bristol-Myers Squibb Co. will post $2.85 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Tocqueville Asset Management L.P. Has $40,041,000 Position in Bristol-Myers Squibb Co. (BMY)” was first posted by Daily Political and is the propert of of Daily Political. If you are accessing this story on another site, it was copied illegally and republished in violation of United States & international copyright laws. The original version of this story can be viewed at http://www.dailypolitical.com/2016/11/30/tocqueville-asset-management-l-p-has-40041000-position-in-bristol-myers-squibb-co-bmy.html.

Several research firms have commented on BMY. Leerink Swann reaffirmed an “outperform” rating and issued a $69.00 price target on shares of Bristol-Myers Squibb in a report on Sunday, October 9th. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Thursday, October 20th. Morgan Stanley lowered shares of Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and set a $63.00 price target on the stock. in a report on Friday, August 5th. Jefferies Group reaffirmed a “hold” rating and issued a $57.00 price target (down from $69.00) on shares of Bristol-Myers Squibb in a report on Monday, September 12th. Finally, Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Bristol-Myers Squibb in a report on Monday, September 12th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus target price of $67.51.

In other Bristol-Myers Squibb news, Director Lamberto Andreotti sold 21,600 shares of the company’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $56.87, for a total value of $1,228,392.00. Following the sale, the director now owns 334,499 shares of the company’s stock, valued at $19,022,958.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.24% of the stock is currently owned by company insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

5 Day Chart for NYSE:BMY

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co. (NYSE:BMY).

Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with MarketBeat.com's FREE daily email newsletter.